Critz Stuart D, Cohen Michael V, Downey James M
Department of Cell Biology and Neuroscience, MSB 2342, University of South Alabama College of Medicine, Mobile, AL 36688, United States.
Vascul Pharmacol. 2005 Apr-May;42(5-6):201-9. doi: 10.1016/j.vph.2005.02.007. Epub 2005 Apr 9.
Acetylcholine (ACh) and bradykinin (BK) are potent pharmacological agents which mimic ischemic preconditioning (IPC) enabling hearts to resist infarction during a subsequent period of ischemia. The cardioprotective pathways activated by BK but not ACh may also protect when activated at reperfusion. ACh and BK stimulate Gi/o-linked receptors and ultimately mediate protection by opening mitochondrial ATP-sensitive potassium channels with the generation of reactive oxygen species that act as second messengers to activate protein kinase C (PKC). There appear to be key differences, however, in the pathways prior to potassium channel opening for these two receptors. This review aims to summarize what is currently known about pharmacological preconditioning by ACh and BK with an emphasis on differences that are seen in the signal transduction cascades. Understanding the cellular basis of protection by ACh and BK is a critical step towards developing pharmacological agents that will prevent infarction during ischemia resulting from coronary occlusion or heart attack.
乙酰胆碱(ACh)和缓激肽(BK)是强效药理剂,它们模拟缺血预处理(IPC),使心脏在随后的缺血期能够抵抗梗死。缓激肽而非乙酰胆碱激活的心脏保护途径在再灌注时激活也可能具有保护作用。乙酰胆碱和缓激肽刺激与Gi/o偶联的受体,并最终通过开放线粒体ATP敏感性钾通道来介导保护作用,同时产生活性氧作为第二信使来激活蛋白激酶C(PKC)。然而,这两种受体在钾通道开放之前的途径似乎存在关键差异。本综述旨在总结目前关于乙酰胆碱和缓激肽的药理预处理的已知情况,重点关注信号转导级联中出现的差异。了解乙酰胆碱和缓激肽的细胞保护基础是开发能够预防冠状动脉闭塞或心脏病发作导致的缺血期间梗死的药理剂的关键一步。